Immune Response Profiles Articles & Analysis
11 news found
CD Genomics, an excellent leader in genomics and bioinformatics, has unveiled a groundbreaking leap forward in TCR-Seq technology, poised to revolutionize immune repertoire profiling. With an unwavering commitment to innovation and precision, CD Genomics continues to redefine the genomics research landscape. TCR-Seq, short for T Cell Receptor Sequencing, is an ...
CD Genomics, a renowned leader in genomics and next-generation sequencing (NGS) applications, has unveiled its cutting-edge HLA typing solutions, revolutionizing immune profiling and transplantation compatibility assessment. The human leukocyte antigen (HLA) system plays a crucial role in immune regulation and determining transplantation compatibility. HLA typing, the process of identifying ...
We’re honored to be named the 2022 Overall Immunology Company of the Year by BioTech Breakthrough. Ozette’s computational immune profiling tech breaks through complex, highly dimensional datasets to revolutionize our understanding of the human immune system. BioTech Breakthrough recognizes Ozette for accelerating scientific collaboration with automated and interpretable single-cell ...
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic ...
New York City- and Tel Aviv-based Immunai said the acquisition would allow it to expand its target discovery and drug development capabilities and that Nebion's experience curating public gene expression datasets would help Immunai grow its Annotated Multiomic Immunological Cell Atlas, or AMICA. "As with other machine learning endeavors like autonomous driving or NLP, having the right data is ...
ByImmunai
Since launching in 2018, the New York City-based company has focused its efforts on multiomic profiling of the immune system and building its Annotated Multiomic Immune Cell Atlas (AMICA). ...
ByImmunai
DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body. INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's ...
INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss ...
This will improve the ability to identify immune responses and acquired immunity, which is desperately needed to deal with the COVID-19 crisis. ...
For cell therapies with high manufacturing costs, a slight variation in cell therapy products can have a significant influence on a patient’s response to the therapy. Immunai has developed a vertically-integrated platform for multi-omic single-cell profiling that offers a broader view of the immune system in states of health, disease, and ...
ByImmunai
It is encouraging that our AI and bioinformatics platform can design vaccine blueprints that have the potential to induce a broad immune response, that may not only be protective for the global population, but also stimulate a long-lived memory immune responses against SARS-CoV-2 and its future mutated ...